Melanoma genomics managing your risk study.

The Melanoma Genomics Managing Your Risk Study is a randomised controlled trial with the aim to establish if; providing personal genomic risk information (from DNA testing) modifies preventive behaviours, compared to receiving standard prevention advice. The study includes an assessment of ethical, psycho-social and economic considerations. If found to be effective and cost-effective, this ‘proof of concept’ intervention study will inform the responsible introduction of genomic testing into the health system for melanoma prevention at a population-level. Eligible participants include: those aged between 18-69 years; never diagnosed with melanoma; and, of European decent. The cost-effectiveness of the genomic risk intervention compared to standard prevention advice alone, from the Australian health system perspective is a two-stage analysis:

• A within-trial economic evaluation at 12 months, reporting the cost for a defined reduction in daily standard erythemal doses, stratified by phenotypic risk group (i.e. primary outcome); and
• A modelled evaluation will extrapolate the intermediate trial outcomes over the longer term to report definitive health outcomes including the cost per melanoma or other skin cancer avoided, and the cost per life year saved.

Additional analyses will determine whether a person’s risk propensity (i.e. risk seeking to risk averse) modifies the effect of the intervention.

See ANZCTR for full trial details >